Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations

키워드

참고문헌 (56)

1. Antonia SJ, "Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC", N Engl J Med, 379, pp.2342~2350 (2018)
2. NSCLC Meta-analysis Collaborative Group, "Preoperative chemotherapy for non-small-cell lung cancer : a systematic review and meta-analysis of individual participant data", Lancet, 383, pp.1561~1571 (2014)
3. Forde PM, "Neoadjuvant PD-1 blockade in resectable lung cancer", N Engl J Med, 378, pp.1976~1986 (2018)
4. Cascone T, "Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable nonsmall cell lung cancer : the phase 2 randomized NEOSTAR trial", Nat Med, 27, pp.504~514 (2021)
5. Cascone T, "Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer : the phase 2 platform NEOSTAR trial", Nat Med, 29, pp.593~604 (2023)
6. Lv C, "Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma(NEOS) : a multicenter, single-arm, open-label phase 2b trial", Lung Cancer, 178, pp.151~156 (2023)
7. Zhang C, "Neoadjuvant crizotinib in resectable locally advanced non-small cell lung cancer with ALK rearrangement", J Thorac Oncol, 14, pp.726~731 (2019)
8. Shu CA, "Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-smallcell lung cancer : an open-label, multicentre, single-arm, phase 2 trial", Lancet Oncol, 21, pp.786~795 (2020)
9. Rothschild SI, "SAKK 16", 14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial, 2021, pp.39, 2872~2880
10. Provencio M, "Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer(NADIM) : an open-label, multicentre, single-arm, phase 2 trial", Lancet Oncol, 21, pp.1413~1422 (2020)
11. Hellmann MD, "Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint", Lancet Oncol, 15, pp.e42~e50 (2014)
12. Forde PM, "Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer", N Engl J Med, 386, pp.1973~1985 (2022)
13. Wakelee H, "Perioperative pembrolizumab for early-stage nonsmall-cell lung cancer", N Engl J Med, 389, pp.491~503 (2023)
14. Weissferdt A, "Agreement on major pathological response in NSCLC patients receiving neoadjuvant chemotherapy", Clin Lung Cancer, 21, pp.341~348 (2020)
15. Pataer A, "Major pathologic response and prognostic score predict survival in patients with lung cancer receiving neoadjuvant chemotherapy", JTO Clin Res Rep, 3, pp.100420~ (2022)
16. Travis WD, "IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy", J Thorac Oncol, 15, pp.709~740 (2020)
17. Mouillet G, "Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials", J Thorac Oncol, 7, pp.841~849 (2012)
18. Pataer A, "Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy", J Thorac Oncol, 7, pp.825~832 (2012)
19. Rosner S, "Association of pathologic complete response and long-term survival outcomes among patients treated with neoadjuvant chemotherapy or chemoradiotherapy for NSCLC : a meta-analysis", JTO Clin Res Rep, 3, pp.100384~ (2022)
20. Provencio M, "Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer", N Engl J Med, 389, pp.504~513 (2023)
21. Ortega-Franco A, "Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer : a narrative review", Transl Lung Cancer Res, 9, pp.2656~2673 (2020)
22. 임성원, "Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer", The Korean Journal of Internal Medicine, 34(1), pp.50~59 (2019), 대한내과학회[DOI]
23. Lim Jeong Uk, "Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse", Tuberculosis and Respiratory Diseases, 86(1), pp.14~22 (2023), 대한결핵및호흡기학회[DOI]
24. Pignon JP, "Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group", J Clin Oncol, 26, pp.3552~3559 (2008)
25. Scott J. Antonia, "Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer", Tuberculosis and Respiratory Diseases, 81(1), pp.29~41 (2018), 대한결핵및호흡기학회
26. Fransen MF, "Tumor-draining lymph nodes are pivotal in PD-1", PD-L1 checkpoint therapy, 2018, pp.3, e124507~
27. Francis DM, "Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy", Sci Transl Med, 12, pp.eaay3575~ (2020)
28. du Bois H, "Tumor-draining lymph nodes : at the crossroads of metastasis and immunity", Sci Immunol, 6, pp.eabg3551~ (2021)
29. Gaudreau PO, "Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC", J Thorac Oncol, 16, pp.127~139 (2021)
30. Topalian SL, "Neoadjuvant checkpoint blockade for cancer immunotherapy", Science, 367, pp.eaax0182~ (2020)
31. Matzner P, "Harnessing cancer immunotherapy during the unexploited immediate perioperative period", Nat Rev Clin Oncol, 17, pp.313~326 (2020)
32. Liu J, "Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease", Cancer Discov, 6, pp.1382~1399 (2016)
33. Felip E, "Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010):a randomised, multicentre, open-label, phase 3 trial", Lancet, 398, pp.1344~1357 (2021)
34. O’Brien M, "Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS", KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial, 2022, pp.23, 1274~1286
35. Felip E, "Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA nonsmall-cell lung cancer(IMpower010) : a randomised, multicentre, open-label, phase III trial", Ann Oncol, 34, pp.907~919 (2023)
36. William WN Jr, "Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy", J Thorac Oncol, 8, pp.222~228 (2013)
37. Katz SI, "Radiologic pseudoprogression during anti-PD-1 therapy for advanced non-small cell lung cancer", J Thorac Oncol, 13, pp.978~986 (2018)
38. Bao X, "Multiparametric MRI for evaluation of pathological response to the neoadjuvant chemo-immunotherapy in resectable non-small-cell lung cancer", Eur Radiol (2023)[DOI]
39. Lee HY, "Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer", J Thorac Oncol, 5, pp.497~503 (2010)
40. Gao S, "Neoadjuvant PD-1 inhibitor(Sintilimab)in NSCLC", J Thorac Oncol, 15, pp.816~826 (2020)
41. Wislez M, "Neoadjuvant durvalumab for resectable non-small-cell lung cancer(NSCLC) : results from a multicenter study(IFCT-1601 IONESCO)", J Immunother Cancer, 10, pp.e005636~ (2022)
42. Bott MJ, "Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer", J Thorac Cardiovasc Surg, 158, pp.269~276 (2019)
43. Tong BC, "Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer", J Thorac Cardiovasc Surg, 163, pp.427~436 (2022)
44. Kato S, "Hyperprogressors after immunotherapy : analysis of genomic alterations associated with accelerated growth rate", Clin Cancer Res, 23, pp.4242~4250 (2017)
45. Juwhan Choi, "Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors", Immune Network, 20(1), pp.1~21 (2020), 대한면역학회[DOI]
46. Matsuo N, "Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy", Invest New Drugs, 39, pp.1150~1158 (2021)
47. Song Y, "Anti-angiogenic agents in combination with immune checkpoint inhibitors : a promising strategy for cancer treatment", Front Immunol, 11, pp.1956~ (2020)
48. Reck M, "Atezolizumab plus bevacizumab and chemotherapy in nonsmall-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial", Lancet Respir Med, 7, pp.387~401 (2019)
49. Provencio M, "Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer(NADIM phase II trial)", J Clin Oncol, 40, pp.2924~2933 (2022)
50. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
51. Le DT, "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade", Science, 357, pp.409~413 (2017)
52. Olivares-Hernández A, "Influence of DNA mismatch repair(MMR)system in survival and response to immune checkpoint inhibitors(ICIs)in nonsmall cell lung cancer(NSCLC) : retrospective analysis", Biomedicines, 10, pp.360~ (2022)
53. Hu W, "Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer", Cancer Med, 6, pp.962~974 (2017)
54. Yue D, "Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients", Transl Lung Cancer Res, 11, pp.263~276 (2022)
55. Verzè M, "Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer : a systematic review", Transl Lung Cancer Res, 11, pp.2588~2600 (2022)
56. Li S, "Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer", Nat Commun, 14, pp.8~ (2023)